AfterRaise/Companies/Oblenio Bio

Oblenio Bio

Oblenio Bio is a company which specializes in the treatment of autoimmune diseases. From its funding announcement.

$62M Series BRaised 4 months agoCambridge, USAOtherUSA
Visit website →

In their own words

What Oblenio Bio says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "company which specializes in the treatment of autoimmune diseases". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Oblenio Bio is today

Oblenio Bio announced a Series B round of $62M on 25 June 2026, led by Pfizer Ventures.

Latest round
Series B
Amount
$62M
Announced
25 June 2026
Headquarters
Cambridge, USA
Sector
Other
Investors
Also participating
Deep Track Capital, GV, Aditum Bio
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

55
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
19/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 25 June 2026
    $62M Series B
    Led by Pfizer Ventures.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Accelerated hiring across functions
  • Commercial scale-up

Opportunities this could create

  • Operations hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers
  • Commercial leadership

Based on the Other sector, a Series B round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 25 June 2026$62M Series B announced
  • 25 June 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Oblenio Bio is open to

Not yet specified

Oblenio Bio has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Oblenio Bio

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Oblenio Bio?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Other companies

See the sector